Outpost Bio is building a Lab-in-the-Loop platform that marries automated experimentation with machine-learning models to unravel the complex interactions between human microbiology and health outcomes. By continuously feeding experimental data back into its algorithms, the company generates proprietary, human-derived functional datasets at scale. These models aim to aid pharmaceutical partners in lowering clinical risk, optimizing drug formulations, and bolstering regulatory submissions. Beyond pharma, the technology can evaluate how prebiotics, botanicals, and other ingredients affect microbial communities for food and consumer-health applications. The current focus is on expanding both the experimental infrastructure and the machine-learning stack to enhance model accuracy and throughput. Although still at a pre-revenue stage, the company has secured initial funding to accelerate platform development and commercial engagement with R&D teams across multiple industries.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2026